Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 8-15

  Malek, Anastasia ^a,b   Schäfer, Reinhold ^a   Tchernitsa, Oleg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ATRASENTAN; CISPLATIN; ENDOTHELIN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GELATINASE A; GELATINASE B; IMATINIB; KERATINOCYTE GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGESTERONE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SEMAXANIB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CALCIUM HOMEOSTASIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

APOPTOSIS; CELL GROWTH PROCESSES; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMANS; OVARIAN NEOPLASMS;

EID: 74649086620     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.10.005     Document Type: Review

References (123)

1. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3 (2004) 355-366
2. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics, 2001. CA Cancer J Clin 51 (2001) 15-36
3. Bartlett J.M., Langdon S.P., Simpson B.J., et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73 (1996) 301-306
4. Hellstrom I., Goodman G., Pullman J., Yang Y., and Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61 (2001) 2420-2423
5. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 283-290
6. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
7. Han E.S., Lin P., and Wakabayashi M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol (2009)
8. Choudhury A., Charo J., Parapuram S.K., et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108 (2004) 71-77
9. Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., and Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53 (1993) 4550-4554
10. Apte S.M., Bucana C.D., Killion J.J., Gershenson D.M., and Fidler I.J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 93 (2004) 78-86
11. Dabrow M.B., Francesco M.R., McBrearty F.X., and Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71 (1998) 29-37
12. Apte S.M., Fan D., Killion J.J., and Fidler I.J. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10 (2004) 897-908
13. Garofalo A., Naumova E., Manenti L., et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 9 (2003) 3476-3485
14. Kacinski B.M., Carter D., Mittal K., et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 137 (1990) 135-147
15. Chambers S.K., Wang Y., Gertz R.E., and Kacinski B.M. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55 (1995) 1578-1585
16. Fang X., Schummer M., Mao M., et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582 (2002) 257-264
17. Tanyi J.L., Morris A.J., Wolf J.K., et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63 (2003) 1073-1082
18. Umezu-Goto M., Tanyi J., Lahad J., et al. Lysophosphatidic acid production and action: validated targets in cancer?. J Cell Biochem 92 (2004) 1115-1140
19. Pustilnik T.B., Estrella V., Wiener J.R., et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5 (1999) 3704-3710
20. Aponte M., Jiang W., Lakkis M., et al. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68 (2008) 5839-5848
21. Jeong K.J., Park S.Y., Seo J.H., et al. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40 (2008) 607-616
22. Herman W.H., and Simonson M.S. Nuclear signaling by endothelin-1. A Ras pathway for activation of the c-fos serum response element. J Biol Chem 270 (1995) 11654-11661
23. Bagnato A., Tecce R., Di C.V., and Catt K.J. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res 57 (1997) 1306-1311
24. Del B.D., Di C.V., Biroccio A., et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61 (2002) 524-532
25. Rosano L., Salani D., Di C.V., Spinella F., Natali P.G., and Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 103 Suppl. 48 (2002) 306S-309S
26. Salani D., Rosano L., Di C.V., et al. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) 103 Suppl. 48 (2002) 318S-3121S
27. Rosano L., Spinella F., Salani D., et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63 (2003) 2447-2453
28. Zheng W., Lu J.J., Luo F., et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76 (2000) 80-88
29. Venkatakrishnan G., Salgia R., and Groopman J.E. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 275 (2000) 6868-6875
30. Cunat S., Hoffmann P., and Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94 (2004) 25-32
31. Bardin A., Hoffmann P., Boulle N., et al. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res 64 (2004) 5861-5869
32. Taube M., Hockenstrom T., Isaksson M., Lindgren P.R., and Backstrom T. Effects of sex steroids on survival and receptor expression in ovarian epithelial tumour cells. Int J Oncol 22 (2003) 1257-1262
33. Wright J.W., Stouffer R.L., and Rodland K.D. Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture. Mol Cell Endocrinol 208 (2003) 1-10
34. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
35. Bowman A., Gabra H., Langdon S.P., et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8 (2002) 2233-2239
36. Semczuk A., Postawski K., Przadka D., Rozynska K., Wrobel A., and Korobowicz E. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors. Eur J Gynaecol Oncol 25 (2004) 484-488
37. Russell S.E., and McCluggage W.G. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203 (2004) 617-619
38. Tchernitsa O.I., Sers C., Zuber J., et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 23 (2004) 4536-4555
39. Cox A.D., and Der C.J. Ras family signaling: therapeutic targeting. Cancer Biol Ther 1 (2002) 599-606
40. Friday B.B., and Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14 (2008) 342-346
41. Choi K.C., Auersperg N., and Leung P.C. Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol 1 (2003) 71
42. Wong A.S., Kim S.O., Leung P.C., Auersperg N., and Pelech S.L. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 82 (2001) 305-311
43. Givant-Horwitz V., Davidson B., Lazarovici P., et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91 (2003) 160-172
44. McPhillips F., Mullen P., Monia B.P., et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 85 (2001) 1753-1758
45. Szaniawska B., Gawrychowski K., and Janik P. The effect of protein kinase C inhibitors on invasion of human ovary cancer cells. Neoplasma 45 (1998) 7-11
46. Advani R., Peethambaram P., Lum B.L., et al. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100 (2004) 321-326
47. Oza A.M., Elit L., Swenerton K., et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol 89 (2003) 129-133
48. Steinmetz R., Wagoner H.A., Zeng P., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18 (2004) 2570-2582
49. Takai N., Hamanaka R., Yoshimatsu J., and Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 24 (2005) 287-291
50. Worsley S.D., Ponder B.A., and Davies B.R. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64 (1997) 189-195
51. Dhar K.K., Branigan K., Parkes J., et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 81 (1999) 1174-1181
52. Barbieri F., Lorenzi P., Ragni N., et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 66 (2004) 310-315
53. Sawasaki T., Shigemasa K., Shiroyama Y., et al. Cyclin E mRNA overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation. J Soc Gynecol Investig 8 (2001) 179-185
54. Farley J., Smith L.M., Darcy K.M., et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63 (2003) 1235-1241
55. Marone M., Scambia G., Giannitelli C., et al. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 75 (1998) 34-39
56. Masciullo V., Scambia G., Marone M., et al. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 74 (1997) 390-395
57. Baykal A., Thompson J.A., Xu X.C., et al. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 11 (2004) 297-302
58. Kushner D.M., Paranjape J.M., Bandyopadhyay B., et al. 2-5A Antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 76 (2000) 183-192
59. Arts H.J., de J.S., Hollema H., Ten H.K., van der Zee A.G., and de Vries E.G. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92 (2004) 794-800
60. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81 (2001) 380-390
61. Malik S.T., Naylor M.S., East N., Oliff A., and Balkwill F.R. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26 (1990) 1031-1034
62. Radke J., Schmidt D., Bohme M., Schmidt U., Weise W., and Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 56 (1996) 83-87
63. Brustmann H. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. Gynecol Oncol 92 (2004) 268-276
64. Barvaux V.A., Lorigan P., Ranson M., et al. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther 3 (2004) 1215-1220
65. Aguirre D., Boya P., Bellet D., et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9 (2004) 797-805
66. Sasaki H., Sheng Y., Kotsuji F., and Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60 (2000) 5659-5666
67. Li J., Feng Q., Kim J.M., et al. Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142 (2001) 370-380
68. Cohen C., Lohmann C.M., Cotsonis G., Lawson D., and Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 16 (2003) 574-583
69. Ferrandina G., Legge F., Martinelli E., et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92 (2005) 271-277
70. Abedini M.R., Qiu Q., Yan X., and Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23 (2004) 6997-7004
71. Elpek G.O., Karaveli S., Simsek T., Keles N., and Aksoy N.H. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 111 (2003) 523-530
72. Hu W., Wu W., Yeung S.C., Freedman R.S., Kavanagh J.J., and Verschraegen C.F. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res 22 (2002) 665-672
73. Yamamoto K., Okamoto A., Isonishi S., Ochiai K., and Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 168 (2001) 173-181
74. Shayesteh L., Lu Y., Kuo W.L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
75. Hu L., Zaloudek C., Mills G.B., Gray J., and Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6 (2000) 880-886
76. Altomare D.A., Wang H.Q., Skele K.L., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23 (2004) 5853-5857
77. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 202 (2003) 89-96
78. Fujioka T., Takebayashi Y., Kihana T., et al. Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep 8 (2001) 249-255
79. Gregoire L., Rabah R., Schmelz E.M., Munkarah A., Roberts P.C., and Lancaster W.D. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res 7 (2001) 4280-4287
80. Auersperg N., Pan J., Grove B.D., et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96 (1999) 6249-6554
81. Cavallaro U. N-cadherin as an invasion promoter: a novel target for antitumor therapy?. Curr Opin Investig Drugs 5 (2004) 1274-1278
82. Springer D.L., Auberry D.L., Ahram M., et al. Characterization of plasma membrane proteins from ovarian cancer cells using mass spectrometry. Dis Markers 19 (2003) 219-228
83. Strobel T., Swanson L., and Cannistra S.A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 57 (1997) 1228-1232
84. Burleson K.M., Casey R.C., Skubitz K.M., Pambuccian S.E., Oegema Jr. T.R., and Skubitz A.P. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93 (2004) 170-181
85. Beck V., Herold H., Benge A., et al. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol 37 (2005) 590-603
86. Strobel T., and Cannistra S.A. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73 (1999) 362-367
87. Davidson B., Goldberg I., Reich R., et al. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90 (2003) 248-257
88. Lessan K., Aguiar D.J., Oegema T., Siebenson L., and Skubitz A.P. CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 154 (1999) 1525-1537
89. McEver R.P. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J 14 (1997) 585-591
90. Mitsuoka C., Ohmori K., Kimura N., et al. Regulation of selectin binding activity by cyclization of sialic acid moiety of carbohydrate ligands on human leukocytes. Proc Natl Acad Sci USA 96 (1999) 1597-1602
91. Chhieng D.C., Rodriguez-Burford C., Talley L.I., et al. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 34 (2003) 1016-1021
92. Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C., and Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161 (2002) 1215-1221
93. Heimburg S., Oehler M.K., Papadopoulos T., Caffier H., Kristen P., and Dietl J. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res 19 (1999) 2527-2529
94. Minderman H., Vanhoefer U., Toth K., Minderman M.D., and Rustum Y.M. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer 78 (1996) 2427-2436
95. Kiguchi K., Iwamori M., Mochizuki Y., et al. Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Le(x)-determinant in the dissemination potential. Jpn J Cancer Res 89 (1998) 923-932
96. Rump A., Morikawa Y., Tanaka M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279 (2004) 9190-9198
97. Suzuki M., Kobayashi H., Tanaka Y., et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int J Cancer 104 (2003) 289-302
98. Rasmussen H.S., and McCann P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75 (1997) 69-75
99. Ueda J., Kajita M., Suenaga N., Fujii K., and Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 22 (2003) 8716-8722
100. Giatromanolaki A., Sivridis E., Tsikouras P., Manavis I., Maroulis G., and Koukourakis M.I. Angiogenesis and vascular survival ability in ovarian adenocarcinomas. Virchows Arch 445 (2004) 521-526
101. Sood A.K., Fletcher M.S., Coffin J.E., et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190 (2004) 899-909
102. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153 (1998) 1249-1256
103. Ahmed S.I., Thomas A.L., and Steward W.P. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 16 Suppl. 4 (2004) 59-63
104. Salani D., Taraboletti G., Rosano L., et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157 (2000) 1703-1711
105. Bagnato A., and Natali P.G. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2 (2004) 16
106. Thijssen V.L., Brandwijk R.J., Dings R.P., and Griffioen A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 299 (2004) 286-293
107. Hibbs K., Skubitz K.M., Pambuccian S.E., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165 (2004) 397-414
108. Lee B.C., Cha K., Avraham S., and Avraham H.K. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 24 (2004) 847-851
109. Santin A.D., Zhan F., Bellone S., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112 (2004) 14-25
110. Ono K., Tanaka T., Tsunoda T., et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60 (2000) 5007-5011
111. Schwartz D.R., Kardia S.L., Shedden K.A., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (2002) 4722-4729
112. Schaner M.E., Ross D.T., Ciaravino G., et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14 (2003) 4376-4486
113. Jazaeri A.A., Lu K., Schmandt R., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 36 (2003) 53-59
114. Shridhar V., Lee J., Pandita A., et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61 (2001) 5895-5904
115. Tapper J., Kettunen E., El-Rifai W., Seppala M., Andersson L.C., and Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 128 (2001) 1-6
116. Lancaster J.M., Dressman H.K., Whitaker R.S., et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11 (2004) 51-59
117. Berchuck A., Iversen E.S., Lancaster J.M., et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190 (2004) 910-925
118. Selvanayagam Z.E., Cheung T.H., Wei N., et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154 (2004) 63-66
119. Gillet J.P., Macadangdang B., Fathke R.L., Gottesman M.M., and Kimchi-Sarfaty C. The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol 542 (2009) 5-54
120. Tsuruta Y., Pereboeva L., Breidenbach M., et al. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 14 (2008) 3582-3588
121. Adib T.R., Henderson S., Perrett C., et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 90 (2004) 686-692
122. Sawiris G.P., Sherman-Baust C.A., Becker K.G., Cheadle C., Teichberg D., and Morin P.J. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 62 (2002) 2923-2928
123. Malek A., Bakhidze E., Noske A., et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123 (2008) 348-356